Livdelzi (Seladelpar Lysine) Patent Expiration, LOE Window & CMS Spending
Livdelzi (Seladelpar Lysine) by Gilead Sciences: FDA Orange Book core substance LOE 2027-09-13 (last listed 2038-03-13), 0 AB generics, $15.6M 2024 CMS Part D & Medicaid spend, and $12,606 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Gilead Sciences |
| FDA Application & Pathway | N217899 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2027-09-13 |
| Last Listed Patent or Exclusivity Date | 2038-03-13 |
| Orange Book Patents (*PED Extensions) | 6 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $15.6M |
| 2024 Medicare Part D Spend | $13.7M |
| 2024 Medicaid Spend | $1.9M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($12,606 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.